Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Cancer data for good : a history of the Victorian Cancer Registry / / Thomas Kehoe
| Cancer data for good : a history of the Victorian Cancer Registry / / Thomas Kehoe |
| Autore | Kehoe Thomas |
| Pubbl/distr/stampa | Singapore : , : Palgrave Macmillan, , [2022] |
| Descrizione fisica | 1 online resource (164 pages) |
| Disciplina | 636.80896994 |
| Soggetto topico | Cancer - Reporting |
| ISBN |
9789811949876
9789811949869 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910624384003321 |
Kehoe Thomas
|
||
| Singapore : , : Palgrave Macmillan, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Chemotherapy protocols and infusion sequence : schedule considerations in cancer treatment / / Iago Dillion Lima Cavalcanti
| Chemotherapy protocols and infusion sequence : schedule considerations in cancer treatment / / Iago Dillion Lima Cavalcanti |
| Autore | Cavalcanti Iago Dillion Lima |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (330 pages) |
| Disciplina | 636.80896994 |
| Soggetto topico |
Cancer - Chemotherapy
Infusion therapy |
| ISBN |
9783031108396
9783031108389 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: Polypharmacy in Cancer Therapy -- 1.1 Polypharmacy: Challenges in the Treatment of Chronic Diseases -- 1.2 Scenario of Polypharmacy in Cancer Treatment -- 1.3 Drug Interactions -- 1.3.1 Pharmacodynamic Interactions -- 1.3.2 Pharmacokinetic Interactions -- 1.4 Advantages in Drug Association -- 1.5 Risks of Polypharmacy -- References -- Chapter 2: Combined Therapy for the Treatment of Cancer -- 2.1 Anticancer Therapy -- 2.2 Combination Therapy in Cancer -- 2.2.1 Challenges in Combination Therapy -- 2.3 Toxicity of Combination Therapy for Cancer Treatment -- 2.3.1 Toxicity in the Treatment of Breast Cancer -- 2.3.2 Toxicity in the Treatment of Lung Cancer -- 2.3.3 Toxicity in the Treatment of Colorectal Cancer -- 2.3.4 Toxicity in the Treatment of Prostate Cancer -- 2.3.5 Toxicity in the Treatment of Cervical Cancer -- 2.3.6 Toxicity in the Treatment of Head and Neck Cancer -- 2.3.7 Toxicity in the Treatment of Lymphomas -- References -- Chapter 3: Importance of the Infusion Order in the Treatment of Cancer -- 3.1 Drug Infusion Therapy -- 3.1.1 Types of Infusion According to Administration Time -- 3.2 Dilution of Drugs and Their Stability -- 3.3 Risks of Chemotherapy Infusion -- 3.3.1 Drug Extravasation -- 3.3.1.1 Irritating Antineoplastics -- 3.3.1.2 Vesicant Antineoplastics -- 3.4 Concept and Importance of Infusion Order -- 3.4.1 Factors That May Influence in the Order of Infusion of Antineoplastic Agents -- References -- Chapter 4: Chemotherapeutic Protocols for the Treatment of Breast Cancer -- 4.1 Breast Cancer: Epidemiology -- 4.2 Pathophysiology of Breast Cancer -- 4.3 Molecular Subtypes of Breast Cancer -- 4.4 Breast Cancer Treatment Modalities -- 4.5 Adjuvant Chemotherapy -- 4.5.1 AC Protocol (Doxorubicin and Cyclophosphamide).
4.5.2 ACT, T-AC, or AC-T Protocol (Doxorubicin, Cyclophosphamide, and Paclitaxel) -- 4.5.3 ACTT Protocol (Doxorubicin, Cyclophosphamide, Paclitaxel, and Trastuzumab) -- 4.5.4 CMF Protocol (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) -- 4.5.5 FAC Protocol (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) -- 4.5.6 FEC Protocol (5-Fluorouracil, Epirubicin, and Cyclophosphamide) -- 4.5.7 FEC-D Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, and Docetaxel) -- 4.5.8 FEC-DT Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.5.9 DAC (Docetaxel, Doxorubicin, and Cyclophosphamide) and DC (Docetaxel and Cyclophosphamide) Protocols -- 4.5.10 TDC Protocol (Trastuzumab, Docetaxel, and Cyclophosphamide) -- 4.5.11 DCARBT Protocol (Docetaxel, Carboplatin, and Trastuzumab) -- 4.6 Chemotherapy in Locally Advanced Breast Cancer -- 4.6.1 AC-DT Protocol (Doxorubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.6.2 CT-AC Protocol (Carboplatin, Paclitaxel, Doxorubicin, and Cyclophosphamide) -- 4.7 Chemotherapy in Advanced Breast Cancer -- 4.7.1 GEMD Protocol (Gemcitabine and Docetaxel) -- 4.7.2 GEMP Protocol (Gemcitabine and Cisplatin) -- 4.7.3 GEMT Protocol (Gemcitabine and Paclitaxel) -- 4.7.4 PTRAD Protocol (Pertuzumab, Trastuzumab, and Docetaxel) -- 4.7.5 PTRAT Protocol (Pertuzumab, Trastuzumab, and Paclitaxel) -- 4.7.6 TRVIN Protocol (Trastuzumab and Vinorelbine) -- References -- Chapter 5: Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer -- 5.1 Epidemiological Profile of Cancers of the Gastrointestinal Tract -- 5.2 Pathophysiology of Colorectal Cancer -- 5.2.1 Adjuvant Chemotherapy for the Treatment of Resectable Colorectal Cancer -- 5.2.1.1 CAPOX Protocol (Oxaliplatin and Capecitabine) -- 5.2.1.2 FL Protocol (5-Fluorouracil and Leucovorin). 5.2.1.3 FOLFOX Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.1.4 RALOX Protocol (Oxaliplatin and Raltitrexed) -- 5.2.2 Chemotherapy for the Treatment of Advanced Unresectable Colorectal Cancer -- 5.2.2.1 CAPB Protocol (Capecitabine and Bevacizumab) -- 5.2.2.2 CETIR Protocol (Cetuximab and Irinotecan) -- 5.2.2.3 FOLFIRI Protocol (Irinotecan, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.2.4 CAPIRI Protocol (Capecitabine and Irinotecan) -- 5.2.2.5 CAPIRIB Protocol (Capecitabine, Irinotecan, and Bevacizumab) -- 5.2.2.6 CAPOXB Protocol (Oxaliplatin, Bevacizumab, and Capecitabine) -- 5.2.2.7 FOLFIRIB Protocol (5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, Irinotecan, and Bevacizumab) -- 5.2.2.8 FOLFIRIPAN Protocol (5-Fluorouracil, Leucovorin, Irinotecan, and Panitumumab) -- 5.2.2.9 FOLFOXB Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Bevacizumab) -- 5.2.2.10 FOLFOXPAN Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Panitumumab) -- 5.3 Pathophysiology of Esophageal and Stomach Cancers -- 5.3.1 Chemotherapy for the Treatment of Esophageal and Stomach Cancer -- 5.3.1.1 FOLFOXT Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Trastuzumab) -- 5.3.1.2 FLOT Protocol (Oxaliplatin, 5-Fluorouracil, Leucovorin, and Docetaxel) -- 5.3.1.3 CTRT Protocol (Carboplatin, Paclitaxel, and Radiotherapy) -- 5.3.1.4 FUC Protocol (5-Fluorouracil and Cisplatin) -- 5.3.1.5 CCAPRT Protocol (Cisplatin, Capecitabine, and Radiotherapy) -- 5.3.1.6 CCAPT Protocol (Cisplatin, Capecitabine, and Trastuzumab) -- 5.3.1.7 CFUT Protocol (Cisplatin, 5-Fluorouracil, and Trastuzumab). 5.3.1.8 CAPOXT Protocol (Capecitabine, Oxaliplatin, and Trastuzumab) -- 5.3.1.9 RAMP Protocol (Paclitaxel and Ramucirumab) -- 5.3.1.10 ECCAP Protocol (Epirubicin, Cisplatin, and Capecitabine) -- 5.4 Pathophysiology of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1 Chemotherapy for the Treatment of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1.1 GEMCIS Protocol (Gemcitabine and Cisplatin) -- 5.4.1.2 FOLFIRINOX Protocol (Irinotecan, Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Leucovorin) -- 5.4.1.3 GEMCAP Protocol (Capecitabine and Gemcitabine) -- 5.4.1.4 GEMABR Protocol (Gemcitabine and Nab-Paclitaxel) -- 5.5 Pathophysiology of Liver Cancer -- 5.5.1 Chemotherapy for the Treatment of Liver Cancer -- 5.5.1.1 Nivolumab and Ipilimumab Protocol -- 5.5.1.2 Atezolizumab and Bevacizumab Protocol -- 5.6 Pathophysiology of Carcinoid and Neuroendocrine Tumors -- 5.6.1 Chemotherapy for the Treatment of Carcinoid and Neuroendocrine Tumors -- 5.6.1.1 ETCIS Protocol (Etoposide and Cisplatin) -- 5.6.1.2 DS Protocol (Doxorubicin and Streptozotocin) -- 5.7 Pathophysiology of Anal Cancer -- 5.7.1 Chemotherapy in the Treatment of Anal Cancer -- 5.7.1.1 FUMRT Protocol (5-Fluorouracil, Mitomycin C, and Radiotherapy) -- 5.7.1.2 CAPMRT Protocol (Capecitabine, Mitomycin C, and Radiotherapy) -- References -- Chapter 6: Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer -- 6.1 Epidemiological Profile of Genitourinary Cancers -- 6.2 Pathophysiology of Bladder Cancer -- 6.2.1 Chemotherapy for the Treatment of Bladder Cancer -- 6.2.1.1 BCGIFN Protocol (BCG and Interferon) -- 6.2.1.2 GEMDOC Protocol (Gemcitabine and Docetaxel) -- 6.2.1.3 MVAC Protocol (Methotrexate, Vinblastine, Doxorubicin, and Cisplatin) -- 6.3 Pathophysiology of Prostate Cancer -- 6.3.1 Chemotherapy for the Treatment of Prostate Cancer. 6.4 Testicular Cancer -- 6.4.1 Chemotherapy for the Treatment of Testicular Cancer -- 6.4.1.1 BEP Protocol (Bleomycin, Etoposide, and Cisplatin) -- 6.4.1.2 VIP Protocol (Etoposide, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.3 TAXGEM Protocol (Paclitaxel and Gemcitabine) -- 6.4.1.4 TIP Protocol (Paclitaxel, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.5 VEIP Protocol (Vinblastine, Cisplatin, Ifosfamide, and Mesna) -- 6.5 Pathophysiology of Kidney Cancer -- 6.5.1 Chemotherapy for the Treatment of Kidney Cancer -- 6.5.1.1 PEMAX Protocol (Pembrolizumab and Axitinib) -- 6.5.1.2 Avelumab and Axitinib Protocol -- References -- Chapter 7: Chemotherapeutic Protocols for the Treatment of Gynecological Cancer -- 7.1 Epidemiological Profile of Gynecological Cancers -- 7.2 Pathophysiology of Ovarian Cancer -- 7.2.1 Chemotherapy for the Treatment of Epithelial Ovarian Cancer -- 7.2.1.1 CABR Protocol (Carboplatin and Abraxane) -- 7.2.1.2 CAPBEV Protocol (Carboplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.3 CISP Protocol (Cisplatin and Paclitaxel) -- 7.2.1.4 CISPBEV Protocol (Cisplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.5 CAD Protocol (Carboplatin and Docetaxel) -- 7.2.1.6 CAG Protocol (Carboplatin and Gemcitabine) -- 7.2.1.7 PLDC Protocol (Pegylated Liposomal Doxorubicin and Carboplatin) -- 7.2.1.8 BEVG Protocol (Bevacizumab and Gemcitabine) -- 7.2.1.9 BEVPLD Protocol (Bevacizumab and Pegylated Liposomal Doxorubicin) -- 7.2.1.10 BEVP Protocol (Bevacizumab and Paclitaxel) -- 7.2.2 Chemotherapy for the Treatment of Non-epithelial Ovarian Cancer -- 7.3 Pathophysiology of Cervical Cancer -- 7.3.1 Chemotherapy for the Treatment of Cervical Cancer -- 7.4 Pathophysiology of Endometrial Cancer -- 7.4.1 Chemotherapy for the Treatment of Endometrial Cancer -- 7.5 Pathophysiology of Gestational Trophoblastic Neoplasia. 7.5.1 Chemotherapy for the Treatment of Gestational Trophoblastic Neoplasia. |
| Record Nr. | UNINA-9910619286503321 |
|
Cavalcanti Iago Dillion Lima
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Computational mathematics modeling in cancer analysis : irst international workshop, CMMCA 2022, held in conjunction with MICCAI 2022, Singapore, September 18, 2022, proceedings / / edited by Wenjian Qin [and three others]
| Computational mathematics modeling in cancer analysis : irst international workshop, CMMCA 2022, held in conjunction with MICCAI 2022, Singapore, September 18, 2022, proceedings / / edited by Wenjian Qin [and three others] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (171 pages) |
| Disciplina | 636.80896994 |
| Collana | Lecture Notes in Computer Science Ser. |
| Soggetto topico | Cancer - Imaging |
| ISBN | 3-031-17266-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996490353903316 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Computational Mathematics Modeling in Cancer Analysis : First International Workshop, CMMCA 2022, Held in Conjunction with MICCAI 2022, Singapore, September 18, 2022, Proceedings / / edited by Wenjian Qin, Nazar Zaki, Fa Zhang, Jia Wu, Fan Yang
| Computational Mathematics Modeling in Cancer Analysis : First International Workshop, CMMCA 2022, Held in Conjunction with MICCAI 2022, Singapore, September 18, 2022, Proceedings / / edited by Wenjian Qin, Nazar Zaki, Fa Zhang, Jia Wu, Fan Yang |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (171 pages) |
| Disciplina |
636.80896994
616.99400113 |
| Collana | Lecture Notes in Computer Science |
| Soggetto topico |
Image processing - Digital techniques
Computer vision Computer engineering Computer networks Machine learning Computers Computer Imaging, Vision, Pattern Recognition and Graphics Computer Engineering and Networks Machine Learning Computing Milieux Càncer Diagnòstic per la imatge Models matemàtics |
| Soggetto genere / forma |
Congressos
Llibres electrònics |
| ISBN |
9783031172663
3031172663 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cellular Architecture on Whole Slide Images Allows the Prediction of Survival in Lung Adenocarcinoma -- Is More Always Better? Effects of Patch Sampling in Distinguishing Chronic Lymphocytic Leukemia from Transformation to Diffuse Large B-cell Lymphoma -- Repeatability of Radiomic Features against Simulated Scanning Position Stochasticity across Imaging Modalities and Cancer Subtypes: A Retrospective Multi-Institutional Study on Head-and-Neck Cases -- MLCN: Metric Learning Constrained Network for Whole Slide Image Classification with Bilinear Gated Attention Mechanism -- NucDETR: End-to-End Transformer for Nucleus Detection in Histopathology Images -- Self-supervised learning based on a pre-trained method for the subtype classification of spinal tumors -- CanDLE: Illuminating Biases in Transcriptomic Pan-Cancer Diagnosis -- Cross-Stream Interactions: Segmentation of Lung Adenocarcinoma Growth Patterns -- Modality-collaborative AI model Ensemble for Lung Cancer Early Diagnosis -- Clustering-based Multi-instance Learning Network for Whole Slide Image Classification -- Multi-task Learning-driven Volume and Slice Level Contrastive Learning for 3D Medical Image Classification -- Light Annotation Fine Segmentation: Histology Image Segmentation based on VGG Fusion with Global Normalisation CAM -- Tubular Structure-Aware Convolutional Neural Networks for Organ at Risks Segmentation in Cervical Cancer Radiotherapy -- Automatic Computer-aided Histopathologic Segmentation for Nasopharyngeal Carcinoma using Transformer Framework -- Accurate Breast Tumor Identification UsingComputational Ultrasound Image Features. |
| Record Nr. | UNINA-9910595023903321 |
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Target volume delineation and field setup : a practical guide for conformal and intensity-modulated radiation therapy / / edited by Nancy Y. Lee, Jiade J. Lu, and Yao Yu
| Target volume delineation and field setup : a practical guide for conformal and intensity-modulated radiation therapy / / edited by Nancy Y. Lee, Jiade J. Lu, and Yao Yu |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (437 pages) |
| Disciplina | 636.80896994 |
| Collana | Practical Guides in Radiation Oncology |
| Soggetto topico | Cancer - Radiotherapy |
| ISBN | 3-030-99590-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910620196103321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||